1. Introduction/Perspective
Michael Andreeff
2. Genetics and Classification of Acute Myeloid Leukemia
Alison R. Walker and Guido Marcucci:
3. Proteomics of AML to guide Selection of Therapy
Steven M. Kornblau
Part I: Apoptosis
4. Roles of Apoptosis Regulating Bcl-2-Family Genes in AML
John C. Reed
5. Bcl-2 family: Translational aspects
Prithviraj Bose and Steven Grant
6. IAP Family and Proteins as Therapeutic Targets for Acute Myeloid Leukemia
Bing Carter and Michael Andreeff
7. TP53 Mutations in Acute Myeloid Leukemia
Claudia Haferlach and Torsten Haferlach
8. Targeting p53 Tumor Suppressor for AML Therapy
Kensuke Kojima and Lyubumir T. Vassilev
9. AML-Selective Apoptosis Induction by rationally designed Death Ligand Fusion Protein
Edwin Brenner and Wijnand Helfrich
Part II: Signaling
10. PIM Kinases in AML
Varsha. Gandhi and L. Chen
11. Development of Midostaurin as a Tyrosine Kinase Inhabitor
Richard M. Stone and Gabi Motyckova
12. FLT3 in AML
Naval Daver Farhad Ravandi
13. FLT3-ITD. Clinical (Sorafenib/AC220)
Naveen Pemmeraju and Jorge E. Cortes
14. Nucleophosmin (NPM1)
Kapil N. Bhalla and Ramesh Balusu
15. Raf/MEK Pathway
James A. McCubrey, Linda.S. Steelman, Joerg Baesecke, and AlbertoM. Martelli
16. The Role of Translational Medicine in Optimization of Therapies targeting the RAS-MAP Kinase Pathway
Judith S. Sebolt-Leopold
17. Clinical Use of Farnesyltransferase Inhititors
Chezi Ganzel and Jacob M. Rowe
18. The P13K-AKT-mTOR signaling Network in AML
Brandon Beagle and David A. Fruman
19. Targeting the P13 Kinase-mTOR Signaling Pathway in AML
Martin Carroll
20. Aurora kinases
Subrata Sen, Hiroshi Katayama
21. The Clinical Development of Aurora Kinase Inhibitors in Acute Myeloid Leukemia
Kevin R. Kelly, Ciara L. Freeman, and Francis J. Giles
Part III: Epigenetics
22. AML-Deacetylases
Margherita Ghisi and Ricky W. Johnstone
23. Methylation in AML-Clinical Applications
Naveen Pemmaraju, Guillermo Garcia-Manero, Farhad Ravandi
Part IV: Nuclear Receptors
24. Topic: RARa/RXR Part: Basic
Hugues de The
25. Arsenic Trioxide in Untreated APL
Elihu H. Estey
26. Targeting PML-RARα with Retinoids
Eytan M. Stein and Martin S. Tallman
27. NR4A Orphan Receptors as Drug Targets
Steven H. Safe, Syng-Ook Lee, Cong Meng, and Beiyan Zhou
Part V: Cell Surface Receptors
28. Antibody-based Therapeutics Targeting CD33, CD45, and CD66
Roland B. Walter, Oliver W. Press, and Irwin D. Bernstein
Part VI: Stem Cells
29. New Heterogeneity of the Leukemic Stem Cells
Dominique Bonnet
30. Targeting Leukemia Stem Cells
Duane C. Hassane, Monica L. Guzman
Part VII: Microenvironment
31. Regulation of Hematopoiesis by CXCL12/CXCR4 Signaling
Daniel C. Link
32. CXC4/CXCL12 as a Therapeutic Target
Geoffrey L. Uy, John F. DiPersio
33. VLA-4: A Cell's Consequential Encounter
Thalia Papayannopoulou
34. VLA-4 Function and Prognosis in Acute Myeloid Leukemia
Pamela S. Becker, Frederick R. Appelbaum
35. VLA4 in Acute Lymphoblastic Leukemia
Halvard Boenig, Yong-Mi Kim
Part VIII: Hypoxia
36. The Leukemic Bone Marrow Microenvironment: Targeting Hypoxia with Hypoxia Activated Pro-Drugs
Juliana Benito, Marina Konopleva, William R. Wilson
Part IX: Micro-RNAs
37. Topic: miRs as Therapeutic Targets
Maitri Shah, George Calin
38. Clinical Implications of MicroRNAs in AML
Parvathi Ranganathan, Ramiro Garzon
Part X: Metabolism
39. Inhibition of Glycolysis as a Therapeutic Strategy in Acute Myeloid Leukemias
R. Laister, Tak W. Mak, Mark Minden
40. Molecular and Biochemical Basis for the Reprogramming of Intermediary Metabolism in Leu
